Acute Biomechanical Effects of Empagliflozin on Living Isolated Human Heart Failure Myocardium

ConclusionThe addition of empagliflozin to LMS from end-stage heart failure patients cultured in a biomimetic system improves contraction and relaxation kinetics by increasing total contraction duration without diminishing maximum force production. Therefore, we present convincing evidence that SGLT2i can directly act on the myocardium in absence of systemic influences from other organ systems.

Source: Cardiovascular Drugs and Therapy - February 13, 2023 Category: Cardiology Source Type: research